Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $56 from $45 and keeps an Equal Weight rating on the shares. The company’s deal with Novartis is favorable with high upfront payment and milestones, the analyst tells investors in a research note. The deal strengthens PTC’s balance sheet and validates its platform, but transfers development risk, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Novartis deal expedites value creation, says Wells Fargo
- RBC upgrades PTC Therapeutics on ‘transformative’ Novartis deal
- PTC Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
- PTC Therapeutics Partners with Novartis for Huntington’s Program
- PTC Therapeutics enters global license, collaboration agreement with Novartis